Compare UHG & SERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UHG | SERA |
|---|---|---|
| Founded | N/A | 2008 |
| Country | United States | United States |
| Employees | 195 | N/A |
| Industry | Homebuilding | Precision Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 68.8M | 79.5M |
| IPO Year | N/A | 2021 |
| Metric | UHG | SERA |
|---|---|---|
| Price | $1.19 | $2.35 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 79.1K | 54.4K |
| Earning Date | 05-13-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 32.32 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $81,000.00 |
| Revenue This Year | N/A | $554.81 |
| Revenue Next Year | N/A | $517.27 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 5.19 |
| 52 Week Low | $0.99 | $1.37 |
| 52 Week High | $4.78 | $4.09 |
| Indicator | UHG | SERA |
|---|---|---|
| Relative Strength Index (RSI) | 40.93 | 57.85 |
| Support Level | $1.15 | $2.26 |
| Resistance Level | $1.81 | $2.41 |
| Average True Range (ATR) | 0.02 | 0.18 |
| MACD | 0.02 | 0.04 |
| Stochastic Oscillator | 77.78 | 92.68 |
United Homes Group Inc designs, builds and sells homes in high growth markets, including South Carolina, North Carolina, and Georgia. UHG employs a land-light operating, with a focus on the design, construction and sale of entry-level, first, second and third move-up single-family houses. The company principally builds detached single-family houses, and, to a lesser extent, attached single-family houses, including duplex houses and town houses. The company has three reportable segments: GSH South Carolina, Rosewood, and Other.
Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other conditions. The proprietary proteomics and bioinformatics platform of the company helps to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.